Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 8/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.31 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627897 | 0.92 | ROCK2 (0.42) | ROCK2HTR1AROCK1TTBK1PIKFYVE | |
| SCHEMBL29640491 | 0.91 | ROCK2 (0.37) | ROCK2HTR1AROCK1TTBK1PIKFYVE | |
| SCHEMBL29640456 | 0.90 | ROCK2 (0.41) | ROCK2HTR1AROCK1TTBK1PIKFYVE | |
| SCHEMBL29627722 | 0.90 | ROCK2 (0.34) | ROCK2HTR1AROCK1TTBK1PIKFYVE | |
| SCHEMBL29627700 | 0.89 | ROCK2 (0.34) | ROCK2HTR1AROCK1TTBK1PIKFYVE | |
| SCHEMBL29627693 | 0.89 | ROCK2 (0.34) | ROCK2HTR1AROCK1TTBK1PIKFYVE | |
| SCHEMBL29627706 | 0.89 | ROCK2 (0.34) | ROCK2HTR1AROCK1TTBK1PIKFYVE | |
| SCHEMBL29627905 | 0.88 | ROCK2 (0.43) | ROCK2LRRK2ROCK1 | |
| SCHEMBL29627717 | 0.86 | ROCK2 (0.34) | ROCK2HTR1AROCK1TTBK1PIKFYVE | |
| SCHEMBL29627953 | 0.86 | ROCK2 (0.34) | ROCK2HTR1ALRRK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | claimed |
| CN-114502163-A | Ethynylheterocycles as RHO-related coiled coil kinase (ROCK) inhibitors | 安吉昂生物医药公司 | 2022-05-13 | — | — | CN | claimed |
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | disclosed |
| CN-114502163-A | Ethynylheterocycles as RHO-related coiled coil kinase (ROCK) inhibitors | 安吉昂生物医药公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885HTR1A 2175/4885LRRK2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.